Revenue

Surging oil volumes met a $1.4 million capital expenditure spike, exposing the structural realities of energy royalty trusts in a high-price environment.

Grupo Bimbo just landed on TIME’s Best Companies list for the third time. We look past the PR to see how the baking giant balances sustainability and profits.

By swapping heavily regulated CBD for mainstream magnesium, TRIP unlocked mass retail, celebrity equity, and a massive $550 million valuation.

Optimum is bringing ultra-fast 8 Gbps fiber to rural Missouri, but beneath the high school donations lies a high-stakes battle for corporate survival.

Gold.com executes a rare dual transition of its CFO and auditor. Here is how the $25 billion powerhouse navigated the SEC hurdles without missing a beat.

As South Korean retail investors pour billions into US equities, global fintechs like Devexperts are rushing to provide the turnkey infrastructure powering the boom.

As AI data centers face crippling seven-year interconnection delays, NOMAD Power Solutions' mobile batteries offer a lucrative workaround to grid gridlock.

By locking in Roberto Cavalli until 2046, Interparfums and Marquee Brands are rewriting the rules of luxury licensing through deep, long-term investment.

As charitable giving shifts and logistical demands surge, a legacy anti-hunger nonprofit recruits corporate tech and finance executives to modernize its mission.

A new joint venture leverages alternative underwriting and device-locking tech to bring smartphones to the unbanked, reshaping retail telecom distribution.

EPIC Insurance Brokers absorbs a fifth-generation Michigan agency, highlighting the intense consolidation pressure facing century-old independent firms.

A new Southern California distribution deal for an FDA-cleared nerve ablation system could revolutionize treatment for trigeminal neuralgia, but risks remain.

Therabody's Depuffing Wand just secured its second consecutive Allure Best of Beauty Award. Here is how a sports recovery giant conquered prestige skincare.

As venture capital tightens and compliance deadlines loom, Greenly’s €64M acquisition of Normative signals a ruthless consolidation in climate software.

By pairing high fashion with complex pharmacology, Sun Pharma aims to capture a multi-billion dollar autoimmune market—but genetic testing and black-box warnings stand in the way.

By shifting clinical documentation integrity to the point of care, Avo's new AI workflow promises to end physician query fatigue and capture lost revenue.

Kathleen Cook explores how Axsome Therapeutics uses real-world data and novel therapies to solve the hardest problems in modern psychiatric and neurologic care.

Ferrari's 2027 alliance with Rakuten blends elite motorsport with advanced telecom and e-commerce, signaling a new era of tech-driven luxury market expansion.

As personalized therapies fragment drug production into small batches, a new flexible dispensing system aims to eliminate bioprocessing's costly QC bottlenecks.

Ruger has abruptly dropped its anti-takeover poison pill. Helen Davis deconstructs the regulatory and strategic forces behind this transatlantic firearms alliance.